NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization7,931.39 mln
Float49.00 mln
Earnings Date08/06/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
142
Strong upside
Relative Strength
41
/ 100
Slightly lagging
Debt / Equity
0.00
Debt-free
ROE
-43.12
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Nuvalent is a clinical-stage company focused on developing targeted cancer treatments. Its three lead drugs ? Zidesamtinib, Neladalkib, and NVL-330 ? are designed to treat specific types of lung and other cancers by overcoming resistance to existing therapies and reaching tumors in the brain more effectively than current options. All three are currently being tested in clinical trials. Founded in 2017, the company is based in Cambridge, Massachusetts.
